Skip to the main content.

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

As we continue to explore the world of cell and gene therapy, we now take a look at managing costs and scale up risks for medical devices.

Author Dave Seward, discusses how the principles of Quality by Design (QbD) and Design for Manufacture (DfM) can be applicable to ATMPs. Read this blog now!

Driving Innovation in MedTech: An Interview with David Phasey

Driving Innovation in MedTech: An Interview with David Phasey

From home dialysis and hip replacements to rethinking one of medicine’s oldest devices, we’ve spent the last 20 years solving the engineering...

Read More
How do you keep your DPI filling process running reliably shift after shift?

How do you keep your DPI filling process running reliably shift after shift?

There are three main approaches to filling blisters with dry powder for inhalation: vacuum drum, membrane dosing and partial compaction and each has...

Read More
CAR-T cell therapy for cancer: The patient's in the process

CAR-T cell therapy for cancer: The patient's in the process

Around 1,000 people are diagnosed with cancer every day in the UK. Fortunately, outcomes continue to improve, with around half of those diagnosed...

Read More